KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer

The biological functions and mechanisms of oncogenic KRAS(G12D) (KRAS*) in resistance to immune checkpoint blockade (ICB) therapy are not fully understood. We demonstrate that KRAS* represses the expression of interferon regulatory factor 2 (IRF2), which in turn directly represses CXCL3 expression....

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Cell
Egile Nagusiak: Liao, Wenting, Overman, Michael J., Boutin, Adam T., Shang, Xiaoying, Zhao, Di, Dey, Prasenjit, Li, Jiexi, Wang, Guocan, Lan, Zhengdao, Li, Jun, Tang, Ming, Jiang, Shan, Ma, Xingdi, Chen, Peiwen, Katkhuda, Riham, Korphaisarn, Krittiya, Chakravarti, Deepavali, Chang, Andrew, Spring, Denise J., Chang, Qing, Zhang, Jianhua, Maru, Dipen M., Maeda, Dean Y., Zebala, John A., Kopetz, Scott, Alan Wang, Y., DePinho, Ronald A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2019
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6467776/
https://ncbi.nlm.nih.gov/pubmed/30905761
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2019.02.008
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak